Financing - May 24, 2023
Gedea Biotech raises 1.3 million EUR
The money has been raised for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for an ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC) with pHyph, partially financed by a recent grant from Swelife and Medtech4Health, investigating how the vaginal microbiome […]
Biotech Business - May 23, 2023
BioLamina announces release of first batches from new facility
BioLamina announces the release of the first Biolaminin 521 LN batches issued from its new manufacturing facility in Sundbyberg, Sweden. The products, which are now ready for commercialization, have been produced in the latest expansion of BioLamina premises. This facility is dedicated to production and research within process development, matrix biology and cellular assays. The […]
Pharma Business - May 22, 2023
Genmab’s EPKINLY approved by the FDA
Genmab has announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after […]
Agreement - May 17, 2023
IRLAB in agreement with the McQuade Center for Strategic Research and Development
IRLAB Therapeutics has announced the signing of an agreement, with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. Under the agreement MSRD will evaluate the neuropsychiatric compounds IRL757 and IRL942 under exclusivity. MSRD, which identifies and supports early-stage opportunities that can change the landscape […]
Agreement - May 15, 2023
HiloProbe enters partnership with Biocartis
Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state. “We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus […]
New Market - May 15, 2023
AstraZeneca’s Ultomiris approved in the EU
Ultomiris has been approved in the European Union as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). “Just four years since delivering the first approved NMOSD treatment to the EU, we are pleased to once again advance the treatment […]
